文献速递头颈外科

头颈癌患者中新发抑郁、预防性抗抑郁药与生存的关系

De-Novo Depression, Prophylactic Antidepressant, and Survival in Patients With Head and Neck Cancer.
PubMed 文献 · Laryngoscope · 2022-06-22

本研究为随机双盲安慰剂对照试验的二次分析,纳入125例II-IV期头颈癌且基线无抑郁的患者,随机接受预防性草酸艾司西酞普兰(n=60)或安慰剂(n=65)。中位随访5.0年(SD 2.4),中重度抑郁发生率为17.6%,总生存与抑郁发生(HR 0.54 [CI, 0.21-1.43])及预防性抗抑郁药使用(HR 0.64 [CI, 0.34-1.21])均无显著关联。

要点

  • II-IV期头颈癌治疗期间中重度抑郁发生率为17.6%(22/125)。
  • 总生存与中重度抑郁发生无显著关联(HR 0.54 [CI, 0.21-1.43])。
  • 总生存与预防性草酸艾司西酞普兰使用无显著关联(HR 0.64 [CI, 0.34-1.21])。

核心结论

  • 在II-IV期头颈癌治疗患者中,总生存与中重度抑郁发生无显著关联,与预防性草酸艾司西酞普兰使用也无显著关联。
  • 作者认为,预防性抗抑郁药可考虑用于头颈癌患者以预防临床显著抑郁,并可能改善生活质量结局。

研究设计与样本

  • 随机双盲安慰剂对照试验的二次分析,148例 eligible 参与者中125例可评估并随机分配。
  • 预防性草酸艾司西酞普兰组60例,安慰剂组65例。
  • 采用QIDS-SR(范围0-27,评分≥11提示中重度抑郁)评估抑郁发生,并按人口学、肿瘤部位和分期、主要治疗方式分层。
  • 使用单变量和多变量Cox比例风险模型评估总生存差异。
  • 证据等级:2级。

主要发现

  • 125例患者中22例(17.6%)在头颈癌治疗期间出现临床显著抑郁。
  • 平均随访5.0年(SD 2.4)。
  • 按中重度抑郁发生分层,总生存组间相似(HR 0.54 [CI, 0.21-1.43])。
  • 按预防性抗抑郁药使用分层,总生存组间相似(HR 0.64 [CI, 0.34-1.21])。

关键数值与推荐

  • QIDS-SR评分≥11定义中重度抑郁。
  • 中重度抑郁发生率为17.6%(22/125)。

临床怎么用

  • 作者认为,预防性抗抑郁药可考虑用于头颈癌患者以预防临床显著抑郁,并可能改善生活质量结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the association between the development of moderate or greater depression during curative-intent therapy and overall survival (OS) in patients with stages II-IV head and neck cancer (HNC). METHODS: In this secondary analysis of a randomized double-blind placebo-controlled trial, of 148 eligible participants diagnosed with stages II-IV HNC but without baseline depression, 125 were evaluable and were randomly allocated to prophylactic escitalopram oxalate (n = 60) or placebo (n = 65). Participants were followed for development of moderate or greater depression, using Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR, range 0-27, score ≥11 indicated moderate or greater depression), and were stratified by demographics; cancer site and stage; and primary treatment modality (surgery with or without radiotherapy vs. radiotherapy with or without chemotherapy). Single variable and multivariable Cox proportional-hazard models were used to evaluate differences in OS. RESULTS: Clinically significant depression developed in 22 of 125 patients (17.6%) during HNC treatment. The mean follow-up was 5.0 years (SD 2.4). OS was similar for patient groups, when stratified by development of moderate or greater depression (HR 0.54 [CI, 0.21-1.43]) or use of prophylactic antidepressant (HR 0.64 [CI, 0.34-1.21]). CONCLUSION: There was no significant association between OS and development of moderate or greater depression in patients being treated for stages II-IV HNC, or between OS and use of prophylactic antidepressant escitalopram. Prophylactic antidepressant may be considered in patients with HNC for prevention of clinically significant depression and may offer improved quality of life outcomes. LEVEL OF EVIDENCE: 2 Laryngoscope, 133:856-862, 2023.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Panwar A, McGill T, Lydiatt D, et al. De-Novo Depression, Prophylactic Antidepressant, and Survival in Patients With Head and Neck Cancer. Laryngoscope. 2022. PMID: 35730719. doi:10.1002/lary.30249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。